<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801931</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC3457</org_study_id>
    <secondary_id>CHNY-06-533</secondary_id>
    <nct_id>NCT00801931</nct_id>
  </id_info>
  <brief_title>Double Cord Blood Transplantation</brief_title>
  <official_title>Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double umbilical cord blood transplantation (DUCBT) following high dose or reduced intensity
      conditioning will be well-tolerated and result in a high degree of engraftment in patients
      with selected malignant and non-malignant disorders.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant.</measure>
    <time_frame>Until end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.</measure>
    <time_frame>Until end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBI, Thiotepa, Cyclophosphamide, ATG</intervention_name>
    <description>APatients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Thiotepa</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Melphalan, Rabbit ATG</intervention_name>
    <description>Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Fludarabine, Alemtuzumab</intervention_name>
    <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Fludarabine, Rabbit ATG</intervention_name>
    <description>Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
    <arm_group_label>D</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Fludara</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Cyclophosphamide, ATG</intervention_name>
    <description>Patients with Fanconi's Anemia will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and anti-thymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
    <arm_group_label>E</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Cyclosphosphamide, Rabbit ATG,</intervention_name>
    <description>Patients with Selected Hemoglobinopathies and non-malignant diseaseswill begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.</description>
    <arm_group_label>F</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be eligible for double cord blood stem cell transplant (TNC ≥ 4x107/kg
             of two combined units) if available single cord blood has TNC ≤4.0 x 107/kg and they
             lack a matched (5-6/6) family donor, a 10/10 unrelated adult donor, and/or if their
             disease status required emergent stem cell transplant and they could not wait 2-3
             months for searching for a matched unrelated adult donor.

          -  Adequate renal function defined as:Serum creatinine &lt;1.5 x normal, or Creatinine
             clearance or radioisotope GFR &gt;60 ml/min/m2 or &gt;60 ml/min/1.73 m2 or an equivalent GFR
             as determined by the institutional normal range.

          -  Adequate liver function defined as:Total bilirubin &lt;1.5 x normal, or SGOT (AST) or
             SGPT (ALT) &lt;3.0 x normal

          -  Adequate cardiac function defined as:Shortening fraction &gt;27% by echocardiogram, or
             Ejection fraction &gt;47% by radionucleotide angiogram or echocardiogram.

          -  Adequate pulmonary function defined as:Uncorrected DLCO 50% by pulmonary function
             test.For children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% on room air.

        Eligibility for Moderate Intensity, Reduced Intensity Regimen and Fanconi's Anemia
        (Regimens C, D and E)

          -  Adequate renal function defined as: Serum creatinine &lt;2.0 x normal, or Creatinine
             clearance or radioisotope GFR 40 ml/min/m2 or &gt;40 ml/min/1.73 m2 or an equivalent GFR
             as determined by the institutional normal range.

          -  Adequate liver function defined as:Total bilirubin &lt;2.5 x normal, or SGOT (AST) or
             SGPT (ALT) &lt;5.0 x normal

          -  Adequate cardiac function defined as:Shortening fraction of &gt;25% by echocardiogram, or
             Ejection fraction &gt;40% by radionucleotide angiogram or echocardiogram.

          -  Adequate pulmonary function defined as:Uncorrected DLCO &gt;35% by pulmonary function
             test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise
             intolerance, and a pulse oximetry &gt;94% on room air.

        Exclusion Criteria:

          -  Females who are pregnant or breast-feeding

          -  Patients with documented uncontrolled infection at the time of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Satwani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia Presbyterian Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord Blood Transplant</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 25, 2017</submitted>
    <returned>August 22, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

